The global single cell bioinformatics software and services market was estimated to be at $205.2 million in 2020, which is expected to grow with a CAGR of 10.89% and reach $634.8 million by 2031
April 27, 2022 04:15 ET
|
ReportLinker
New York, April 27, 2022 (GLOBE NEWSWIRE) -- Reportlinker.com announces the release of the report "Single Cell Bioinformatics Software and Services Market - A Global and Regional Analysis: Focus on...
Rapid7 Named a Visionary for Second Consecutive Year in Gartner® Magic Quadrant™ for Application Security Testing
April 21, 2022 11:05 ET
|
Rapid7
BOSTON, April 21, 2022 (GLOBE NEWSWIRE) -- Rapid7, Inc. (NASDAQ: RPD), a leading provider of security analytics and automation, today announced it has been recognized as a Visionary by Gartner for...
Tajikistan - Telecoms, Mobile and Broadband - Statistics and Analyses
December 15, 2021 10:33 ET
|
BuddeComm
Sydney, Dec. 15, 2021 (GLOBE NEWSWIRE) -- Just released, this edition of BuddeComm report outlines the latest developments and key trends in the telecoms markets. -...
Rapid7 Named a Visionary in 2021 Gartner Magic Quadrant for Application Security Testing
June 01, 2021 11:32 ET
|
Rapid7
BOSTON, June 01, 2021 (GLOBE NEWSWIRE) -- Rapid7, Inc. (NASDAQ: RPD), a leading provider of security analytics and automation, today announced it has been recognized as a Visionary by Gartner in the...
Advaxis Presents Updated Clinical Data from Ongoing Phase 1/2 Trial of ADXS-503 in NSCLC at the American Society of Clinical Oncology (ASCO) 2021 Annual Meeting
May 19, 2021 17:01 ET
|
Advaxis, Inc.
Updated data show disease control rate of 44% with durable clinical benefit observed beyond one year in patients with disease progression on pembrolizumab Translational data support potential of...
Two Confirmed Responses and Five out of Six Patients with Initial Tumor Reductions from Early Dose Cohorts of SURPASS Trial, Presented at SITC
November 09, 2020 15:18 ET
|
Adaptimmune Therapeutics plc
- Data support continued development of ADP-A2M4CD8 - - On track to start Phase 2 trial in gastroesophageal cancers in the first half of 2021 - PHILADELPHIA, Pa. and OXFORDSHIRE, UK., Nov. 09, 2020...
T-Cell Surface Glycoprotein CD4 Clinical Trial Analysis by DelveInsight
November 09, 2020 09:23 ET
|
DelveInsight Business Research LLP
Los Angeles, USA, Nov. 09, 2020 (GLOBE NEWSWIRE) -- T-Cell Surface Glycoprotein CD4 Clinical Trial Analysis by DelveInsight DelveInsight has recently added “T-cell Surface Glycoprotein CD4 –...
Adaptimmune Provides Full Contents of its SITC Abstract for the Phase 1 SURPASS Trial
October 15, 2020 16:40 ET
|
Adaptimmune Therapeutics plc
PHILADELPHIA and OXFORDSHIRE, United Kingdom, Oct. 15, 2020 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (“Adaptimmune”) (Nasdaq: ADAP), a leader in cell therapy to treat cancer is aware of the...
World Bank critical of Tajikistan's telecom sector
June 22, 2020 12:00 ET
|
BuddeComm
Sydney, June 22, 2020 (GLOBE NEWSWIRE) -- Just released, this edition of Paul Budde Communication’s focus report on Tajikistan outlines the major developments and key aspects in the telecoms...
Global Security Orchestration Automation & Response (SOAR) Market 2019-2025 - $2.3 Billion Industry Opportunity Insights
October 18, 2019 09:16 ET
|
Research and Markets
Dublin, Oct. 18, 2019 (GLOBE NEWSWIRE) -- The "Global Security Orchestration Automation and Response (SOAR) Market (2019-2025)" report has been added to ResearchAndMarkets.com's offering....